To study the clinical efficacy and safety of Xiaoer Jiegan Granule in the treatment of acute upper respiratory tract infection in children.Methods:A total of 108 child patients with acute upper respiratory tract infection admitted to Pediatric Department of Xi'an Children's Hospltal from February 2018 to February 2019 were randomly divided into an observation group and a control group，with 54 cases in each group.The observation group was treated with Xiaoer Jiegan Granule，while the control group was treated with Xiaoer Resuqing Granule.After 3 days of continuous treatment，the clinical efficacy,antipyretic time，symptom score，serum inflammatory cytokine level，incidence of adverse reaction and theother data of the 2 groups were compared.Results:After 1 cycle of treatment，the observation group had a higher curative rate，which was significantly higher than the control group.The effective rate and inefficiency were lower than those of the control group，and the total effective rate was higher than that of the control group(P<0.05).Antipyretic onset time in the observation group and complete antipyretic time were lower than the control group(P<0.05).After treatment，the scores of symptoms such as fever，throat swelling and pain，and nasal congestion in the observation group were lower than those in the control group.After treatment，the serum inflammatory factors in the observation group were lower than that in the control group(P<0.05).During the treatment period，there were 3 cases of watery stool diarrhea and 1 case of skin rash in the control group，and no adverse reactions occurred in the observation group.There were significant differences in the incidence of adverse reactions between the 2 groups(P<0.05).Conclusion:Compared with Xiaoer Resuiqing Granule，Xiaoer Jiegan Granule can shorten the time offever abatement,improve the symptoms of child patients，reduce the level of Serum inflammatory cytokine.It is used for the clinical treatment of pediatric AURI，with remarkable curative effect and safety.And it can be used for clinical promotion.